EuroMedLab 2019

EuroMedLab 2019

Join us for EuroMedLab 2019!

Randox Laboratories will be attending EuroMedLab from the 19th – 23rd May 2019. Our innovative diagnostic solutions have been developed with consolidation and economy in mind, providing cost savings whilst using pioneering technology.

Diagnostics is our passion. We are dedicated to developing solutions that not only meet your needs, but that are of the highest quality, the most reliable and the most cost-effective. We look forward to meeting you in the Barcelona International Convention Centre, at our booth No. 184.

Register your attendance at one of our industry sponsored workshops

The industry specific workshops are open to all congress attendees on a first come, first-served basis.

Development and clinical evaluation of an automated multi-analyte biochip array for rapid stroke diagnosis | Room 116 | Mon, 20 May 2019 , 14:45 – 15:45

Secreted Phospholipases A2 and Cardiovascular Risk | Room 116 | Tue, 21 May 2019 , 12:30 – 13:30

Novel Multiplex Molecular Diagnostics: A Cross-Platform Comparison | Room 117 | Tue, 21 May 2019, 14:45 – 15:45

What can we offer?

  • Biosciences
  • Acusera
  • Qnostics
  • QCMD
  • Reagents
  • RX Series
  • Toxicology
  • Evidence Series

Randox Biosciences is part of Randox Laboratories and is dedicated to advancing scientific discovery, drug development and diagnostics. We provide a variety of services and products to numerous industries including clinical laboratories, biopharma and academic research institutes.

Our revolutionary multiplex Biochip Array Technology includes multiplex protein immunoassays and multiplex nucleic acid arrays, and is delivered via the award winning Evidence range of analysers. Biochip Array Technology is a multi-analyte testing platform facilitating the simultaneous quantitative or qualitative detection of a wide range of analytes from a single sample. Biochip provides a unique platform for assessment in a rapid, accurate and easy to use format.


Vivalytic the newest offering from Randox Biosciences brings innovation to the Molecular Diagnostic industry providing tests for respiratory, genitourinary and hospital acquired infections. The Vivalytic platform is capable of both Hi-Plex and Lo-Plex testing. Nucleic acid extraction, PCR amplification followed by a suite of detection methods are combined in a truly revolutionary, fully automated platform. Manual preparation, cold chain reagents and the use of multiple devices are no longer required making Vivalytic a unique space-saving, hygienic solution for Molecular Diagnostic testing.

Join our workshop on Tuesday 21st May 2019 to learn more about molecular testing and how 44 pathogens can be tested from a single patient sample.


Leading provider of true third-party controls

With over 390 parameters available in our Acusera range, choice and flexibility is guaranteed. Moreover, the availability of truly independent third-party controls coupled with the added advantages of highly accurate target values, excellent stability and unparalleled quality will enhance performance, save valuable time and minimise waste in any laboratory. Our comprehensive range of multi-analyte controls have been uniquely developed with user convenience in mind. By combining more than 100 parameters in a single vial, laboratories can significantly reduce the need for multiple, costly single analyte controls.

Acusera 24.7

Online QC software with real-time peer group statistics

Designed to help you efficiently review QC data from multiple laboratory instruments on one centralised platform, Acusera 24.7 allows quick and easy identification of QC failures and emerging trends.

Unique access to live peer group updates will reduce time and money spent troubleshooting, helping you to instantly discover if an issue is isolated to your lab or a widespread problem. The added benefit of automatically generated statistics including Sigma Scores, Measurement Uncertainty & Total Error as well as fully interactive charts & reports will enable quick and easy performance monitoring.

Acusera Verify

Meet CLIA requirements with accuracy and ease

Acusera Linearity Sets are designed to challenge a larger section of an instruments reportable range and test if a system’s calibration is still valid. Our linearity materials cover a wide range of testing including, CRP, RF, Lipids, Therapeutic Drugs, Esoterics and more. Designed with user convenience in mind, all our linearity sets are supplied in a liquid format, while also presented in varying levels. Our unique combination of analytes enables laboratories to reduce the number of individual products required while ultimately reducing costs and time.

Complimentary, cloud-based data reduction software is supplied with all linearity sets, providing a graphical representation of results for at-a-glance performance assessment.  Access to instantly updated peer group data and automatically generated statistics also helps to speed up data review.

The World’s Largest International EQA scheme

With over 45,000 laboratory participants in more than 133 countries, the Randox International Quality Assessment Scheme (RIQAS) is truly the largest international EQA provider in the world. Our comprehensive product offering currently covers over 360 parameters across 33 flexible programmes. Each RIQAS programme contains a unique combination of parameters meaning laboratories can significantly reduce the number of individual programs required while increasing efficiency and reducing costs. Further benefits to a laboratory include accreditation to ISO 17043:2010, frequent reporting, reduced parameter options and access to comprehensive yet user-friendly reports.

Molecular Infectious Disease Controls

Qnostics is a leading manufacturer of Third Party Quality Control solutions for Molecular Infectious Disease testing. Supplying microbiology/virology laboratories, molecular diagnostic assay manufacturers, EQA providers, pharmaceutical and CRO organisations for over a decade.

Designed to meet the demand of today’s molecular diagnostics laboratory and laboratories carrying out Nucleic Acid Testing (NAT), the Qnostics Molecular Infectious Disease range comprises hundreds of characterised viral, bacterial and fungal targets covering a wide range of Transplant Associated Diseases, Respiratory Infections, Blood Borne Viruses, Sexually Transmitted Infections, Gastrointestinal Diseases and Central Nervous System Diseases.

Join our workshop on Tuesday 21st May 2019 to learn more about molecular testing and how 44 pathogens can be tested from a single patient sample.

Molecular External Quality Control

QCMD is a world leading External Quality Assessment (EQA) / Proficiency Testing (PT) scheme, dedicated to improving the quality of molecular diagnostic assays used in the detection of infectious diseases. With an extensive database of over 2000 participants in over 100 countries, QCMD is one of the largest providers of molecular EQA in the field of infectious disease testing.

EQA participants receive an individual report outlining their performance relative to their method and technology groups. A supplementary report may be commissioned – this includes any additional relevant information regarding the annual EQA distribution, as well as scientific expert commentary and feedback on the overall results within that distribution.

Randox Reagents are internationally recognised as being of the highest quality, offering reliable and rapid results. Our product portfolio consists of 113 clinical chemistry assays, covering a range of testing panels, including: antioxidants, diabetes, drugs of abuse testing, cardiology and lipids, specific proteins, therapeutic drug monitoring and veterinary testing.

Randox are continuously striving to improve diagnostic solutions worldwide.  As a result, Randox have produced 29 niche and superior performance assays, including: 5th Generation Bile Acids, Adiponectin, Aldolase, Copper, Cystatin C, D-3-Hydroxybutyrate, G6PDH, H-FABP, Lipoprotein (a), NEFA, HDL2/3 Cholesterol, sdLDL Cholesterol, Total Antioxidant Status and Zinc.

Enhance your Cardiac Testing Panel with sPLA2-IIA!

sPLA2-IIA is thought to be the most highly expressed enzyme from the secretory phospholipase A2 family. sPLA2-IIA is expressed in the normal arterial wall and its expression is readily up-regulated by inflammatory stimuli. It’s production of fatty acids and biologically active phospholipids plays an important role in platelet, monocyte, and endothelial activation, processes known to be critical steps in atherogenesis.

Join our workshop on Tuesday 21st May 2019 to learn more about sPLA2-IIA’s role in inflammatory conditions, including its prediction in cardiovascular risk.

Renowned for quality and reliability, the RX series leads the way with the world’s most extensive dedicated clinical chemistry test menu comprising routine chemistries, specific proteins, lipids, therapeutic drugs, drugs of abuse, antioxidants, veterinary and diabetes testing. Guaranteeing real cost savings through consolidation of routine and specialised tests onto a single platform, the RX series of analysers delivers excellence in patient care, offering unrivalled precision, accuracy and reliability.

RX misano

The RX misano semi-automated analyser has been developed with the user in mind by incorporating a responsive touch-screen display. The sleek ergonomic design boasts intuitive user-friendly software allowing for test menu personalisation and ease of use. The RX misano is capable of high standard, precise results at a competitive price per test.

RX monaco

The RX monaco is a fully automated solution for low to mid volume clinical chemistry testing offering the ultimate in convenience, performance and confidence. At optimal configuration, the RX monaco performs 170 tests per hour providing cost effective, high quality testing.

RX daytona +

The RX daytona+ is a fully automated, benchtop, clinical chemistry analyser capable of performing high quality testing, with a combined throughput of 450 tests per hour, for accurate results you can trust. The most versatile analyser in its class, the RX daytona+ combines robust hardware and intuitive software with the world leading RX series test menu for unrivalled performance with direct HbA1c testing capabilities.

RX imola

The RX imola is a cost-effective system that delivers consistent high-quality results. Capable of handling the workload of a medium to high throughout laboratory and a combined throughput of 560 tests per hour, the RX imola provides rapid, comprehensive testing on a small footprint analyser with direct HbA1c testing capabilities. The RX imola is a fully automated system with random access and STAT sampling functionality, boosting productivity and saving time when it matters most

RX modena

Capable of performing up to 1,200 tests per hour, with direct HbA1c testing capabilities, the RX modena consolidates all your assay requirements onto one intuitive platform. The RX modena boasts icon based, interactive touch-screen technology adding a modern flair to your laboratory.

Find out more about Direct HbA1c
Book a demonstration of one of our analysers

Randox Toxicology offer the most comprehensive Drugs of Abuse (DoA) test menu across multiple forensic matrices. Our level of expertise in toxicology research and development allows us to adapt quickly to ever changing market influences and develop assays for current and novel drug trends. Excellent assay precision and performance eliminates false reporting, therefore reducing unnecessary confirmatory tests and time lost in the laboratory as a result. Our Biochip Arrays offer CVs typically less than 10%, producing an accurate drug profile to ensure confidence in results.

Evidence series immunoassay analysers guarantee cost-effective, highly accurate and flexible testing solutions. Having been developed to work with patented Biochip Array Technology, this precision multiplex testing platform allows for the simultaneous quantitative or qualitative detection of a wide range of analytes from a single sample.

This multiplex system delivers an unrivalled increase in patient information, offering a more in-depth diagnostic profile with each patient sample. This further analysis places the focus on the diagnosis, and on improving patient outcomes.

Want to know more?

Contact us or book a meeting with us

View our list of scientific posters that will be on display at EuroMedLab

  • Monday 20th May 2019
  • Tuesday 21st May 2019

Rapid simultaneous screening (less than 23 minutes) of twenty drug classes from a single whole blood sample on the biochip analyser Evidence MultiSTAT | Display time: 10.00am – 5.30pm | Presenter: P. Robinson (Randox Toxicology)

Evaluation of the effect of more frequent reporting in analytical performance through the use of an international external quality assessment scheme | Display time: 10.00am – 5.30pm | Presenter: L. Adams (Randox Laboratories Ltd.)

Development of a biochip array for the simultaneous detection of twelve cytokines on the new random access fully automated Evidence Evolution analyser | Display time: 10.00am – 5.30pm | Presenter: G. Donnellan (Randox Teoranta)

Analytical performance evaluation of an assay for the direct measurement of HbA1c in whole blood on RX series analysers of different throughput | Display time: 10.00am – 5.30pm | Presenter: E. Lenehan (Randox Laboratories Ltd)

Development of a new biochip based immunoassay for the determination of the bone formation biomarker N-terminal propeptide of type 1 collagen (P1NP) | Display time: 10.00am – 5.30pm | Presenter: H. Stott  (R&D Randox Biosciences)

Development of a biochip-based immunoassay for the specific detection of the Wnt signalling antagonist DKK1 | Display time: 10.00am – 5.30pm | Presenter: H. Stott  (R&D Randox Biosciences)

Development of a highly specific monoclonal antibody pair for the detection of sclerostin, a regulator of bone turnover | Display time: 10.00am – 5.30pm | A. Connolly (Randox Teoranta)

Biomarker glycosylation evaluation in pancreatic cancer utilizing biochip array technology | Display time: 10.00am – 5.30pm | A. Connolly (Randox Teoranta)

Overcoming the burden of Diabetes and Cardiovascular Disease

The Prevalence 

Cardiovascular disease (CVD) is the number one cause of death globally with more people dying annually from CVD than any other disease state. In 2018, according to the American Heart Association, CVD accounted for nearly 836,546 deaths in the USA (1) with over 17 million known deaths recorded worldwide. It is also proclaimed that around 1.5 million people globally die each year because of diabetes and diabetes related complications. (2) Is there a common link? Can this issue be controlled?

Studies have suggested that diabetes is one of the leading related conditions associated with increased risk of CVD death. A recent study undertaken in 2018 examined the association of many risk factors associated with CVD, the study was broken down by disease state with over 17,000 participants involved. The findings highlighted that 17.9% of these patients suffered from diabetes mellitus and death from a cardiovascular event. (3) Many other pilot and research studies discovered similar findings considering further risk factors such as high blood pressure, abnormal cholesterol and high triglycerides, obesity, lack of exercise and lifestyle choices such as smoking, alcohol and drug abuse. All of which are common with patients who suffer from diabetes, placing them at an increased risk of CVD.

Findings highlighted that over 68% of people aged over 65 living with diabetes die from some form of heart disease with 16% of individuals dying from an ischemic stroke. (4)   The ability to tackle the prevalence of increased death from CVD and diagnosis of diabetes has become a global burden with the international diabetes federation projecting that 592 million people worldwide will have diabetes by 2035. (5)

Worldwide, the increase of diabetes is becoming an economic burden on the patient and healthcare systems mainly due to the direct costs of medical care and the indirect costs of moderated productivity, tied to diabetes and CVD related morbidity and mortality. Many scholars have highlighted economic burden as a primary attribute to both macrovascular and microvascular complications such as coronary artery disease, myocardial infarction, hypertension, peripheral vascular disease, retinopathy, end-stage renal disease and neuropathy. (6)


The RX Series offers the worlds largest clinical chemistry test menu

Overcoming the Burden

As CVD is the most prevalent cause of mortality and morbidity in patients with diabetes, effective treatment and analysis is required to control and decrease the number of CVD deaths across the globe. Tackling this issue head on, the Randox RX series introduce Direct HbA1c which refers to glycated haemoglobin which is a product of haemoglobin (a protein which can be found in red blood cells) and glucose from the blood making it glycated.

Testing for HbA1c provides an indication of what an individual’s average blood sugar level has been over recent weeks/months and is generally considered as an indicator of how well the patient is managing and controlling their diabetes. This is significant for those who suffer from diabetes because the higher the levels of HbA1c, the higher the chance of an individual suffering from further diabetes related issues, therefore testing for HbA1c improves the predictions of a CVD event occurring.

The Randox RX series have Direct HbA1c testing capabilities on the RX Daytona +, RX imola and RX modena. Our latex enhanced immunoturbidimetric method which the RX series utilises makes the test simple and quick to perform. The removal of the pre-dilution step removes the risk of human error compromising your results without the need for a separate HbA1c analyser.

Offering the world’s largest test menu, the RX series has an extensive range of cardiac, diabetes and lipid tests with excellent correlation to gold standard methodologies designed to allow laboratories to expand their testing capabilities onto one single platform, providing cost savings through consolidation.


  1. American Heart Association. (2018). Heart Disease and Stroke Statistics 2018 At-a-Glance.Available:—at-a-glance-ucm_498848.pdf. Last accessed 7th Feb 2019.
  2. World Heart Federation. (2017). Cardiovascular diseases (CVDs) – Global facts and figures.Available: Last accessed 7th Feb 2019.
  3. Gomadam, P et al, (2018). Blood pressure indices and cardiovascular disease mortality in persons with or without diabetes mellitus. Journal of Hypertension. 36 (1), 1-5.
  4. Heart attack and stroke symptoms. (2018). Cardiovascular Disease and Diabetes.Available:–diabetes. Last accessed 7th Feb 2019.
  5. Aguiree F, Brown A, Cho NH, Dahlquist G, Dodd S, Dunning T, Hirst M, Hwang C, Magliano D, Patterson C. (2013) IDF Diabetes Atlas.
  6. Bahia LR, Araujo DV, Schaan BD, Dib SA, Negrato CA, Leão MP, Ramos AJ, Forti AC, Gomes MB, Foss MC, Monteiro RA, Sartorelli D, Franco LJ, Value Health. (2011), 137-40.

Why Choose the Randox RX series?

Why Choose the RX series?

Notorious for quality and reliability, the Randox RX series delivers on precision, reliability and accuracy, revolutionising patient testing in a variety of laboratory types including Clinical Laboratories, University & Research Institutes and Veterinary Laboratories.

The RX series is world renowned for delivering superior performance, our comprehensive test menu comprises over 113 clinical chemistry assays – 22 more than our nearest competitor.  In addition to this we offer superior methodology for many assays with excellent correlation to gold standard methods. Our test menu is constanty expanding and currently covers routine chemistry, specific proteins, lipids, cardiac markers, therapeutic drugs, drugs of abuse, antioxidants and diabetes testing including direct HbA1c testing capabilities.  Designed to meet the needs of your laboratory, our range of novel tests allow laboratories to expand their test menu without expanding their lab ultimately reducing costs, labour and the risk of error without the need for additional / specialised equipment.

With a versatile range of semi-automated and automated analysers, the RX series offers flexibility to suit the needs of all laboratory requirements. Built on the foundations of robust hardware and intuitive software, the RX series will reduce costly test re-runs and potential misdiagnosis.  With minimal analyser downtime significant cost and time savings are a reality.

Our prominent reputation of providing laboratories with unrivalled customer and technical support across the globe surpasses that of any of our competitors complementing our extensive and world leading test menu. We pride ourselves in both the delivery and functionality of high quality clinical chemistry analysers, dedicated reagents and support ensuring accuracy and reliability in reporting patient results.


The RX Series offers the worlds largest clinical chemistry test menu

Offering the World’s Largest Clinical Chemistry Test Menu

Most recently the RX series welcomed the addition of Direct HbA1c to our testing panel, available to be run on the RX Daytona +, RX imola and RX modena. If you are interested in running your assays on a routine biochemistry analyser, Randox offers a large range of high quality routine and niche protein assays that can be run on most automated analysers.

Click to discover more about our world leading RX series Testing menu or contact us today @theRXseries to find out how we can improve your laboratories testing capabilities.

Choose from the RX misano, RX monacoRX daytona+, RX imola and RX modena to start your journey with the RX series today.

The move from Nephelometry to Immunoturbidimetric Testing


In clinical diagnostics, proteins are part of a wide range of biochemical markers used to identify health and disease in patient samples. Proteins play a key role in the human body, as they are involved in almost every process and can be associated to functions and regulatory pathways that are either signature for disease onset or a target for therapeutic intervention.

There are two main methods used to detect proteins in patient samples; nephelometry and immunoturbidimetry.  Nephelometry although traditionally thought to be more sensitive can be expensive due to higher consumable costs.  In addition to this nephelometers can be inefficient and are limited by their test menu.  Immunoturbidimetric tests are an increasingly accepted alternative to nephelometry for specific protein assays, and studies have shown a close correlation between Randox immunoturbidimetric tests and nephelometry. This particularly lies with the latex enhanced immunoturbidimetry methodology utilised by Randox.

Why the RX series?

Renowned for quality and reliability, the RX series excels in clinical testing combining robust hardware, intuitive software and a world leading test menu featuring routine and novel high performing reagents.

Running specific protein tests on the RX series provides laboratories with a wide range of advantages. The move from nephelometric testing to immunoturbidimetric lowers laboratory costs as nephelometry requires the use of dedicated instruments which are much slower, have higher consumable costs and require highly trained personnel, with the disadvantage of not being able to perform any other type of assay on a single platform.

The RX series improves laboratory efficiencies not just saving costs but also time. Our range of routine clinical chemistry analysers provide users with flexibility and versatility through consolidation of testing onto one single platform.


The RX Series of analysers now welcomes the addition of Direct HbA1c Testing on the RX daytona +, RX imola & RX modena

High Performing and Unique Testing Menu

The RX series of specific protein assays assist in the diagnosis and evaluation of various conditions each with excellent sensitivity and limited inference levels. Randox manufacture immunoturbidimetric kits for the study of a wide range of specific proteins including unique products such as Apolipoprotein C-II, Apolipoprotein C-III, Apolipoprotein E, Cystatin C and Microalbumin.

Most recently the RX series welcomed the addition of Direct HbA1c to our testing panel, available to be run on the RX Daytona +, RX imola and RX modena. If you are interested in running your protein assays on a routine biochemistry analyser, Randox offers a large range of high quality routine and niche protein assays that can be run on most automated analysers.

Click to discover more about our world leading RX series Testing menu or contact us today @theRXseries to find out how we can improve your laboratories testing capabilities.

Automation vs. ELISA


The technological developments and scientific innovations in the field of clinical chemistry from the early 1950’s to date have been vast, enhancing laboratory capabilities and providing the necessary support to clinicians and laboratories to improve patient diagnosis and treatment. (1) Laboratory automation today is a complex integration of robotics, computers, liquid handling and numerous other technologies with a fundamental purpose of saving time and improving performance through the elimination of human error.

Complementing this, in the early 1950’s ready-to-use assay reagent kits, with instructions for use introduced a very significant innovation to the field of automation eliminating the process of manually preparing reagent. (2)

Despite the many advancements in automation many clinical laboratories continue to use manual methods such as ELISA for some specialised tests. (3)

Inefficiencies with ELISA based methods

Manual ELISA based techniques are notoriously inefficient and are particularly draining on time and personnel due to the manual intervention required. The manual nature of the method also means there is greater potential for human error ultimately resulting in lack of sensitivity and potential for cross-reactivity. (4,5)

For many laboratories, the transition from traditional ELISA techniques to an automated method for the detection of the same analyte will significantly improve both costs and time.

Renowned for quality and reliability the RX series range of clinical chemistry analysers ensures confidence in patient testing.


The RX Series of analysers allows for automation of specialised tests that previously would have only been possible via traditional ELISA methods e.g. Adiponectin, G-6PDH and Cystatin C.


Expanding Capabilities and Performance

With patient care holding a primary focus on clinical chemistry testing, the RX series range of semi-automated and automated analysers offer versatility to suit all laboratory requirements. Expanding your laboratory’s capabilities with our world leading extensive dedicated test menu offers cost savings through consolidation of both routine and specialised tests. By transitioning analytes historically only available as an ELISA based test, laboratories can expand their offering with ease to both patients and clinicians.

Our open system approach to clinical testing offers unique opportunities for consolidation, most of our unique and high-performance assays may be run on any clinical chemistry instrument without the need for specialised equipment.

Outperforming ELISA methodology, the RX series delivers a testing platform that requires limited or no manual preparation. With ELISA, the test is run on a 96 well plate using only a single assay with recommendations to duplicate or triplicate samples to evacuate the extent of errors, therefore increasing time and costs. The RX series of analysers each have different levels of throughput to adapt to the requirements of all laboratories.  Utilising robust hardware and intuitive software the RX series guarantees accurate and precise patient testing.


  1. Olsen K. The first 110 years of laboratory automation: technologies, applications, and the creative scientist. J Lab Autom. 2012; 17:469-80.
  2. Rosenfeld L. A golden age of clinical chemistry: 1948-1960. Clin Chem. 2000; 46:1705.14.
  3. Kricja LJ, Savory J. International year of chemistry 2011. A guide to the history of clinical chemistry. Clin Chem. 2011; 57:1118-26.
  4. Wild D, Sheehan C, Binder S. Introduction to immunoassay product technology in clinical diagnostic testing. In: Wild D, editor. Immunoassay Handbook: Theory and Applications of Ligand Binding, ELISA and Related Techniques. 4th Oxford, UK: Elsevier; 2013.
  5. Hawker CDED. Laboratory automation: total and subtotal. Clin Lab Med. 2007; 27:749-70.

Randox pioneers health testing innovations at world’s largest diagnostics conference

World-leading medical diagnostics manufacturer Randox Laboratories is this week showcasing advancements in biotechnology at the world’s largest diagnostics conference, being held in Chicago, Illinois.

The American Association of Clinical Chemistry (AACC) Annual Meeting and Clinical Lab Expo, known as the leading event for laboratory medicine worldwide, offers Randox the opportunity to showcase their capabilities to more than 20,000 healthcare professionals and decision makers from around the globe.

“Our pioneering diagnostic technologies are leading the way in innovation and have real potential to transform healthcare around the world,” said Randox Managing Director, Dr Peter FitzGerald.

“At AACC we will be hosting demonstrations of a wide range of our intuitive multiplex analysers, including the revolutionary Randox Evidence Evolution, the world’s first fully automated random-access testing platform, capable of delivering 2640 results in one hour, with the first delivered in just 37 minutes.”

The unique and unrivalled capabilities of the Randox Evidence Evolution are made possible thanks to Randox’s patented Biochip Array Technology, which can currently run 49 different tests simultaneously – ensuring an accurate and reliable diagnosis as fast as possible.

Launching at this year’s AACC event are a number of exciting new tests on the Randox Biochip, the result of a £280 million investment in research and development. Including but not exclusive to a diagnostic test for the differentiation of hemorrhagic and ischemic strokes, an algorithm capable of generating a patient’s Type 1 Diabetes Genetic Risk Score, and a test to diagnose Acute Kidney Injury (AKI) in the participants of pharmaceutical drug trials, these new tests all share the common goal of much earlier and effective diagnosis, to greatly improve healthcare outcomes and reduce the burden on healthcare services.

Dr. FitzGerald continued;

“We remain committed to developing new health diagnostic technologies for a range of the world’s most pressing health issues in need of the most urgent address, and to expanding the business in our key markets, such as the US.

Our very significant investment in research and development means that we have more new tests in development than any other healthcare company in the world and are able each year to bring a wealth of exciting new technologies to the American market.

“We look forward to showcasing our latest innovations at this year’s AACC conference, and how they can be utilised to save, improve and extend lives through the earliest possible diagnosis. Randox technology can truly revolutionise the future of healthcare.”

AACC runs from the 29th July – 2nd August at McCormick Place in Chicago, Illinois. Randox can be found at booth #3624.

For further information visit










Diagnosing diabetes with the RX series

Diabetes is a lifelong condition that causes a person’s blood sugar level to become too high.

If you have diabetes, your body is unable to break down glucose into energy. This is because there’s either not enough insulin to move the glucose, or the insulin produced doesn’t work properly [1] which can lead to serious health complications.

The RX series range of analysers have one of the largest test menus available on the market which includes an extensive diabetes testing panel. Tests within the RX series diabetes panel allow for Diagnosis, Monitoring and Risk Assessment of Diabetes.


An adiponectin test system is a device intended for the quantitative in vitro determination of adiponectin concentration in human serum or plasma.

Adiponectin is a protein hormone, produced and secreted by fat cells (adipocytes), which is normally found in reasonably high concentrations within the blood. Adiponectin regulates the metabolism of lipids and glucose and influences the body’s response to insulin and inflammation.

Adiponectin levels are inversely correlated with abdominal visceral fat (AVF) levels, which have proven to be a strong predictor of several pathologies including metabolic syndrome, type 2 diabetes mellitus (T2DM), cancers and cardiovascular disease (CVD). It is widely recognised that people who are overweight are at a higher risk of developing T2DM, however measure waist circumference and Body Mass Index (BMI) are not enough. As such adiponectin levels are a much more reliable indicator of at-risk patients.

A number of key publications have advocated the testing of adiponectin in clinical settings and concluded that higher adiponectin levels are associated with a lower risk of T2DM across diverse populations.[2]


A fructosamine test system is a device intended for the quantitative in vitro determination of glycated protein (fructosamine) concentration in human serum or plasma.

Fructosamine is a mid-term indicator of diabetic control as it can provide information on a person’s averge blood glucose levels over the preceding 14-21 days.

 Due to the shorter time span of fructosamine, it is often used to evaluate the effectiveness of medication changes and to monitor the treatment of gestational diabetes.


A Haemoglobin A1c test system is a device intended for the quantitative in vitro determination of Haemoglobin A1c concentration in whole blood.

 In a diabetic patient, where blood glucose levels are abnormally elevated, the level of HbA1c also increases proportionally to the level of glucose in the blood and has been widely accepted as an indicator of the mean daily blood glucose concentration over the preceding 6-8 weeks. It is therefore, a long term indicator of diabetic control.

Read our poster on Randox’s development of a new latex enhanced immunoturbidimetric assay for the rapid direct measurement of glycated haemoglobin (HbA1c) applicable to RX series analysers by clicking here. 

 Diagnosing diabetes with the RX series

The RX series range of clinical chemistry analysers have many benefits when testing patients for diabetes. With analysers ranging from the RX misano semi-automated analyser to the RX modena which can perform up to 1200 tests per hour the RX series analysers offer a suitable platform for your laboratory, ensuring results are received in a time efficient manner. Windows based software and easily recognisable icons ensure that the RX series analysers are easy to use and allows for an enhanced laboratory productivity. Laboratory cost savings can also be achieved with a low water consumption available on each RX series analyser.

Other RX series analyser features include:

Diabetes Test Menu:

Consolidate your testing with a comprehensive diabetes testing panel available on the RX series analysers. A large number of tests can be carried out on one platform, including direct HbA1c testing, providing consolidation opportunities and real cost savings.

Accurate Testing:

High quality results are achieved first time, every time. This saves operator time and avoids unnecessary additional costs of repeat testing and reduces the possibility of patient misdiagnosis.

Unrivalled performance:

Built in inventory management system automatically calculates remaining reagent volume and the number of tests available. Superior performance means minimal downtime and swift reporting of results.

If you would like more information in relation to the RX series testing capabilities please contact us by emailing:

Celebrating the Randox Reagents R&D Team this Medical Laboratory Professionals Week!

Medical Laboratory Professionals Week (MLPW) is a week dedicated to increasing public understanding and appreciation for the clinical laboratory profession. During this week, we are taking the opportunity to celebrate the hard work of our Research and Development team. Allow us to provide you an insight into the life changing work of our scientists in the laboratories.

At Randox, our scientists work tirelessly to develop revolutionary diagnostic tests that are used in hospital and research laboratories across the globe.

We spoke to one of our biochemistry R&D Scientists to gain an insight into what working in a clinical chemistry laboratory entails. Emmett Donnelly, Clinical Chemistry R&D Scientist, is involved in the development of new reagents and the improvement of existing reagents. Emmett commented, “[My] role also involves the transfer and testing of existing chemistries onto new analyser platforms. Troubleshooting and resolving customer queries also forms part of a clinical analyst’s role”.  Emmett’s work is vital to ensure that patient tests are performing correctly, and to develop ground-breaking new technologies leading to better patient outcomes. To find out more about the work Emmett does, watch this video below.

Our scientists are committed to research and development and thrive knowing that their novel research is putting them at the forefront of clinical diagnostics.

In fact, prior to beginning work at Randox, Scott Paulin, Clinical Chemistry R&D team, took part in a three month expedition to Antarctica to intensely study human response-based research in athletes. A number of papers have been published in peer reviewed journals as a result of Scott’s research, as the findings have provided a useful insight into the physiological stress and responses associated with an Antarctic ultra-endurance race and nutritional counterstrategies to help maintain immune responses, function body weight and reduce stress markers. Read the full article here.

At Randox, our scientists are of the highest calibre, with vast experience and expertise which ensures we are producing the highest quality range of clinical diagnostic tests.

Excitingly as a result, American astronauts have enlisted our help to test their antioxidant levels before they go to space! This is essential as it ensures astronauts can survive long periods of time away from earth. To find out more about how important our Total Antioxidant Status (TAS) test is for astronauts, read our blog post here.

The invaluable work our scientists undertake in the laboratory is vital to ensure healthcare is advanced globally. Thanks to those in our Research and Development team, we are proud to be able to offer the widest range of clinical chemistry reagents and unique tests for medical diagnosis. Due to our scientist’s dedication to research, a continual focus is placed on developing tests that assess the risk of diseases, rather than diagnosing the illness after it has occurred. As a result, Randox are helping to change healthcare, as patients are provided the ability to take preventative action early. In the words of our R&D scientist Emmett Donnelly, “for me, my work supports the old saying prevention is better than cure”.

We hope you have enjoyed reading about our fantastic team of R&D Scientists! If you would like to find out more about the work of Randox Reagents, please get in contact by emailing: or click here to view our homepage.


How Randox R&D Scientists are helping to change healthcare: An introduction to diagnostics for BSW 2017

In celebration of British Science Week 2017, we will be giving you an introduction to diagnostics, and exploring how Randox Scientists are helping to change healthcare.


You may or may not already know that Randox are one of the leading diagnostics companies globally.  But what exactly does clinical diagnostics involve?  It is one of the fundamental steps of finding out what is wrong with a person when they are ill.  Read on to find out a bit more about diagnostics, and how the Randox Reagents R&D Scientists are helping to change healthcare globally!

What is a diagnostic test?

A diagnostic test is any kind of analysis performed on a patient sample (a sample is typically blood, urine or cerebrospinal fluid (CSF)), to aid in the diagnosis or detection of disease.  The information found from a test can be used to:

  • Diagnose disease
  • Assess the extent of damage
  • Monitor the effectiveness of treatment
  • Confirm a person to be free from disease

Blood flows through all parts of the body, coming into direct contact with every organ and tissue.  Therefore a blood sample’s appearance and composition provide important information on what is happening in the various parts of the body!

So what exactly is being tested in the blood?

Examples of substances that may be tested for the blood include proteins, nutrients, waste products, antibodies, hormones, salts, trace elements or vitamins.  These are sometimes referred to as ‘analytes’, ‘markers’ or ‘biomarkers’.

This is where reagents come in…

A reagent is a substance which is mixed with the patient sample to create a chemical reaction to detect the biomarker.  These reactions are analysed by machines known as analysers.


Using data gathered from both clinical symptoms and laboratory tests, the doctor will follow a sometimes painstaking process of analysis and elimination to perform a successful diagnosis!


Continue reading…

Product Focus: Randox Cardiac

With World Heart Month running throughout February, we have decided to focus this month on Cardiac Markers. Over the next few weeks, we will be taking a look at some of the QC solutions available from Randox.

The accurate diagnosis of a potentially life threatening cardiac event is essential in order to avoid misdiagnosis and/or incorrect treatment. Acusera True Third Party Cardiac Controls have been designed to cover a wide range of cardiac markers at clinical decision levels eliminating the need for additional low level controls at extra expense. Available in a choice of liquid ready-to-use and lyophilised formats, they are ideal for use at the point-of-care and in the lab. Manufactured from 100% human serum, a matrix similar to that of the patient is guaranteed.

Week 1- Acusera Tri-Level Cardiac Control

The Randox Acusera Tri-Level Cardiac control is designed for use in the routine monitoring of both accuracy and precision. Assayed instrument and method specific target values are provided for 7 cardiac markers along with temperature specific target values for CK and CK-MB.

Features & Benefits

  • Lyophilised for enhanced stability
  • 100% human serum
  • Assayed target values provided for 7 cardiac markers
  • Cut off levels for Troponin I and T in line with internationally recommended levels
  • Stable to expiry date at 2°C – 8°C
  • Reconstituted stability of 5 days at 2°C – 8°C or 4 weeks at -20°C

Week 2- Acusera Liquid Cardiac Control

The Randox Acusera Liquid Cardiac control is designed to be both convenient and easy to use. The liquid ready-to-use format makes it ideal for both clinical laboratories and point-of-care testing. Assayed, instrument specific values are provided for an impressive 8 cardiac markers including, NT-ProBNP, D-dimer and Troponin ensuring consolidation and flexibility. Furthermore an open vial stability of 30 days for all analytes helps to keep waste and costs to a minimum.

Features & Benefits

  • Liquid ready-to-use
  • 100% human serum
  • Assayed target values provided for 8 cardiac markers
  • Cut off levels for Troponin I and T in line with internationally recommended levels
  • Stable to expiry date at 2°C – 8°C
  • Open vial stability of 30 days at 2°C – 8°C for all analytes

Week 3 – RIQAS Cardiac Programme

RIQAS is the largest international External Quality Assessment Scheme, with more than 40,000 participants in over 124 countries. World renowned for reducing the number of individual programmes required by even the most demanding laboratories, RIQAS covers 360 parameters across 32 flexible multi-parameter programmes.  Effective consolidation in this way will not only deliver real cost savings but free up storage space and ultimately reduce the time spent preparing multiple samples at each survey.

The RIQAS Cardiac EQA programme is designed to monitor the performance of up to 7 clinically significant cardiac markers. Two flexible reporting options are available to suit the needs of all laboratory sizes.

Features & Benefits

  • Accredited to ISO/IEC 17043
  • Lyophilised for enhanced stability
  • 100% human serum
  • Bi-weekly reporting
  • Submit results and view reports online via RIQAS.Net
  • Register up to five instruments at no extra cost

Week 4 – Acusera 24.7 Live Online Version 2.0

Acusera 24•7 Live Online is an interlaboratory data management and peer group reporting package complementing the Acusera range of true third party quality controls. Designed to assist in the management of daily QC activities, Acusera 24•7 Live Online will help to meet regulatory requirements, improve error detection, reduce false rejections and ensure accurate patient results.

Delivering an online platform for effective QC data management, our software provides unique access to instantly updated real-time peer group data, automatically generated QC statistics, QC multi-rules, interactive charts and comprehensive reports.

Acusera 24•7 Live Online is an essential QC tool for laboratories of all sizes. By participating and implementing our software your laboratory will be able to do the following;

  • Quickly identify trends, system errors and reagent issues, minimising expensive repeat tests
  • Automatically calculate Measurement Uncertainty, Total Error and Sigma Metrics
  • Bridge the gap between daily quality control and external quality assessment
  • Improve EQA performance by eliminating any undetected bias
  • Facilitate regulatory compliance
  • Reduce false rejections through the use of QC multi-rules
  • Increase confidence in assigned QC target values
  • Speed up troubleshooting processes, shortening delays in reporting